Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Novel immunotherapies for multiple myeloma & other exciting developments

Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, National University of Singapore, Singapore, provides an overview of the latest updates in immunotherapies for multiple myeloma. The development of bispecific antibodies and T-cell engagers targeting BCMA and GPRC5D will potentially give patients more treatment options. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.